AstraZeneca Japan Medical Director, MD [clinicaltrials_resource:41ff522dad871583aa76a3663bb8c98c]
Iressa 2nd Line Phase III Study in Japan [clinicaltrials:NCT00252707]ZD6474 Phase IIa Dose Finding Multicentre Study [clinicaltrials:NCT00252746]Iressa Case Control Study in Japan [clinicaltrials:NCT00252759]A Study to Investigate the Pharmacodynamic Effect After Four-week Omeprazole Treatment of Non-erosive Reflux Disease in a Japanese Population [clinicaltrials:NCT00259051]Dose Response Study in Japanese Patients [clinicaltrials:NCT00261417]Comparative Study of Oestradiol Suppression: Zoladex 10.8mg/3 Month vs. 3.6mg/Month in ER +ve EBC Pre-menopausal Patients [clinicaltrials:NCT00303524]clinicaltrials:NCT00305448
overall official [clinicaltrials_vocabulary:overall-official]
AstraZeneca Japan Medical Director, MD [clinicaltrials_resource:41ff522dad871583aa76a3663bb8c98c]
Bio2RDF identifier
41ff522dad871583aa76a3663bb8c98c
Bio2RDF namespace
clinicaltrials_resource
Bio2RDF uri
http://bio2rdf.org/clinicaltrials_resource:41ff522dad871583aa76a3663bb8c98c
affiliation [clinicaltrials_vocabulary:affiliation]
email [clinicaltrials_vocabulary:email]
AZTrial_Results_Posting@astrazeneca.com
last name [clinicaltrials_vocabulary:last-name]
AstraZeneca Japan Medical Director, MD
role [clinicaltrials_vocabulary:role]
Study Director
identifier
clinicaltrials_resource:41ff522dad871583aa76a3663bb8c98c
title
AstraZeneca Japan Medical Director, MD
@en
type
label
AstraZeneca Japan Medical Dire ...... f522dad871583aa76a3663bb8c98c]
@en